NCT04574583 2025-02-03Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)National Institutes of Health Clinical Center (CC)Phase 1/2 Completed12 enrolled 17 charts